BRPI0821855B8 - composto, composição farmacêutica, e, uso de um composto ou sal farmaceuticamente aceitável do mesmo - Google Patents
composto, composição farmacêutica, e, uso de um composto ou sal farmaceuticamente aceitável do mesmo Download PDFInfo
- Publication number
- BRPI0821855B8 BRPI0821855B8 BRPI0821855A BRPI0821855A BRPI0821855B8 BR PI0821855 B8 BRPI0821855 B8 BR PI0821855B8 BR PI0821855 A BRPI0821855 A BR PI0821855A BR PI0821855 A BRPI0821855 A BR PI0821855A BR PI0821855 B8 BRPI0821855 B8 BR PI0821855B8
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical composition
- present
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 150000003839 salts Chemical class 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 108010041052 DNA Topoisomerase IV Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000704 physical effect Effects 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007337693 | 2007-12-27 | ||
JP2007-337693 | 2007-12-27 | ||
PCT/JP2008/073686 WO2009084614A1 (ja) | 2007-12-27 | 2008-12-26 | イミダゾールカルボニル化合物 |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0821855A2 BRPI0821855A2 (pt) | 2015-06-16 |
BRPI0821855B1 BRPI0821855B1 (pt) | 2019-08-27 |
BRPI0821855B8 true BRPI0821855B8 (pt) | 2021-05-25 |
Family
ID=40824327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0821855A BRPI0821855B8 (pt) | 2007-12-27 | 2008-12-26 | composto, composição farmacêutica, e, uso de um composto ou sal farmaceuticamente aceitável do mesmo |
Country Status (11)
Country | Link |
---|---|
US (2) | US8536197B2 (pt) |
EP (1) | EP2226322B1 (pt) |
JP (2) | JP5586234B2 (pt) |
KR (1) | KR101578954B1 (pt) |
CN (1) | CN101959882B (pt) |
BR (1) | BRPI0821855B8 (pt) |
CA (1) | CA2710959C (pt) |
ES (1) | ES2535085T3 (pt) |
HK (1) | HK1147259A1 (pt) |
TW (1) | TWI498115B (pt) |
WO (1) | WO2009084614A1 (pt) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI498115B (zh) | 2007-12-27 | 2015-09-01 | Daiichi Sankyo Co Ltd | 咪唑羰基化合物 |
GB2498080A (en) * | 2011-12-21 | 2013-07-03 | Redx Pharma Ltd | Derivatives of oseltamivir |
US9034874B2 (en) * | 2012-07-20 | 2015-05-19 | Novartis Ag | Carbamate/urea derivatives |
CN104016925B (zh) * | 2014-06-17 | 2016-03-30 | 遵义医学院 | 4-烷基咪唑-2-羧酸的合成方法 |
CN104059020B (zh) * | 2014-06-27 | 2016-08-31 | 湖南海利常德农药化工有限公司 | 1-芳基-5-羟基吡唑的制备方法 |
MD3316969T2 (ro) | 2015-07-02 | 2022-07-31 | Janssen Sciences Ireland Unlimited Co | Compuși antibacterieni |
MY184406A (en) * | 2015-09-30 | 2021-04-01 | Daiichi Sankyo Co Ltd | Hydroxyalkyl thiadiazole derivatives |
US11179396B2 (en) | 2016-06-16 | 2021-11-23 | Janssen Sciences Ireland Uc | Heterocyclic compounds as antibacterials |
EA201991997A1 (ru) | 2017-03-01 | 2020-01-22 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Комбинированная терапия |
WO2018169092A1 (en) | 2017-03-14 | 2018-09-20 | Daiichi Sankyo Company, Limited | N-phosphonoxymethyl prodrugs of hydroxyalkyl thiadiazole derivatives |
US20210070747A1 (en) | 2017-03-24 | 2021-03-11 | Taisho Pharmaceutical Co., Ltd. | 2(1h)-quinolinone derivative |
WO2020048949A1 (en) | 2018-09-03 | 2020-03-12 | Univerza V Ljubljani | New class of dna gyrase and/or topoisomerase iv inhibitors with activity against gram-positive and gram-negative bacteria |
CN113045564A (zh) * | 2019-12-27 | 2021-06-29 | 上海天慈国际药业有限公司 | 一种阿培利司的制备方法 |
CN111592495A (zh) * | 2020-07-06 | 2020-08-28 | 上海启讯医药科技有限公司 | 一种2-正丁基-4-氯-5甲酰基咪唑的制备方法 |
JP2023538969A (ja) * | 2020-08-31 | 2023-09-12 | エフ. ホフマン-ラ ロシュ アーゲー | 抗菌薬としてのイミダゾール-ピラゾール誘導体 |
WO2022049011A1 (en) * | 2020-09-01 | 2022-03-10 | F. Hoffmann-La Roche Ag | Imidazole-pyrazole derivatives with anti-bacterial properties |
EP4263503A1 (en) | 2020-12-17 | 2023-10-25 | Univerza V Ljubljani | New n-phenylpyrrolamide inhibitors of dna gyrase and topoisomerase iv with antibacterial activity |
CN114436991A (zh) * | 2021-12-25 | 2022-05-06 | 上海泰坦科技股份有限公司 | 一种2-氨基噻唑类化合物的合成方法 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179277A (en) * | 1976-03-12 | 1979-12-18 | Bayer Aktiengesellschaft | 4,5-Dichloroimidazole-2-carboxylic acid derivatives |
US4602095A (en) * | 1983-12-29 | 1986-07-22 | General Foods Corporation | 3-hydroxy-4-alkyloxyphenyl heterocyclic aromatic carboxylates |
GB8531665D0 (en) * | 1985-12-23 | 1986-02-05 | Wyeth John & Brother Ltd | Indole derivatives |
US5082847A (en) * | 1990-07-18 | 1992-01-21 | Syntex (U.S.A.) Inc. | Carbostyril compounds connected via an oxyalkyl group with a piperidine ring and having pharmaceutical utility |
IL101851A (en) * | 1991-06-13 | 1996-05-14 | Janssen Pharmaceutica Nv | History 01 -) 4 - Pipridinyl - and Pipridinylidene (- Imidazo] A-1,2 [Pirolo, Thiano or Purano (] 3,2 [Azpin, their preparation and pharmaceutical preparations containing them and composition |
EP0585500A1 (en) | 1992-09-04 | 1994-03-09 | Merrell Dow Pharmaceuticals Inc. | Diaryl piperazineacetamides as antimuscarinic agents |
US5318975A (en) * | 1993-02-16 | 1994-06-07 | Berlex Laboratories, Inc. | 5-pyrimdineamine derivatives |
TW593317B (en) * | 1993-06-21 | 2004-06-21 | Janssen Pharmaceutica Nv | Positive cardiac inotropic and lusitropic pyrroloquinolinone derivatives |
EP1007525A1 (en) * | 1997-08-29 | 2000-06-14 | Zeneca Limited | Aminometyl oxooxazolidinyl benzene derivatives |
CA2322311C (en) * | 1998-03-04 | 2009-10-13 | Bristol-Myers Squibb Company | Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors |
AR030537A1 (es) * | 1999-11-05 | 2003-08-27 | Abbott Lab | Acidos quinolincarboxilicos y naftiridincarboxilico antibacterianos |
EP1399160A4 (en) * | 2001-06-12 | 2004-08-25 | Merck & Co Inc | NR2B RECEPTOR ANTAGONISTS FOR TREATING OR PREVENTING MIGRAINE |
US7217726B2 (en) * | 2002-08-22 | 2007-05-15 | Orchid Chemicals & Pharmaceuticals Limited | Antibacterial agents |
WO2004041795A1 (en) * | 2002-10-30 | 2004-05-21 | Guilford Pharmaceuticals Inc. | Novel inhibitors of dipeptidyl peptidase iv |
EP1613613B1 (en) * | 2003-04-11 | 2021-06-02 | Genzyme Corporation | Cxcr4 chemokine receptor binding compounds |
WO2005003087A2 (en) * | 2003-07-01 | 2005-01-13 | Orchid Chemicals And Pharmaceuticals Ltd. | Oxazole derivatives as antibacterial agents |
GB0317516D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as PDE4 inhibitors |
TW200526626A (en) * | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
GB0321509D0 (en) * | 2003-09-13 | 2003-10-15 | Astrazeneca Ab | Chemical compounds |
WO2005030128A2 (en) * | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Pyrazole modulators of metabotropic glutamate receptors |
EP1740584B9 (en) * | 2004-04-28 | 2010-06-09 | Takeda Pharmaceutical Company Limited | Fused quinoline derivative and use thereof |
WO2006038001A1 (en) * | 2004-10-06 | 2006-04-13 | Celltech R & D Limited | Aminopyrimidine derivatives as jnk inhibitors |
CN101084208A (zh) * | 2004-10-22 | 2007-12-05 | 詹森药业有限公司 | 作为c-fms激酶抑制剂的芳族酰胺 |
AU2005299837A1 (en) * | 2004-10-22 | 2006-05-04 | Janssen Pharmaceutica, N.V. | Inhibitors of c-fms kinase |
SI1831159T1 (sl) | 2004-12-21 | 2010-04-30 | Hoffmann La Roche | Derivati tetralina in indana ter njune uporabe |
WO2006087544A2 (en) | 2005-02-18 | 2006-08-24 | Astrazeneca Ab | Pyrrole derivatives as dna gyrase and topoisomerase inhibitors |
US8399489B2 (en) | 2005-02-18 | 2013-03-19 | Astrazeneca Ab | Antibacterial piperdine derivatives |
US20080161306A1 (en) | 2005-02-18 | 2008-07-03 | Brian Sherer | Pyrrole Derivatives as Dna Gyrase and Topoisomerase Inhibitors |
GB0503646D0 (en) * | 2005-02-22 | 2005-03-30 | Novartis Ag | Organic compounds |
EP1861396A1 (en) | 2005-03-04 | 2007-12-05 | AstraZeneca AB | Tricyclic derivatives of azetidine and pyrrole with antibacterial activity |
JP2008531671A (ja) | 2005-03-04 | 2008-08-14 | アストラゼネカ アクチボラグ | 化合物 |
CN101142194B (zh) * | 2005-03-14 | 2012-10-10 | 顶点制药有限责任公司 | 吲哚衍生物,组合物及用作β-分泌酶抑制剂的方法 |
US20060281788A1 (en) * | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
EP1902022A1 (en) * | 2005-07-12 | 2008-03-26 | Glaxo Group Limited | Piperazine heteroaryl derivates as gpr38 agonists |
US20080312211A1 (en) | 2005-12-23 | 2008-12-18 | Astrazeneca Ab | Antibacterial Pyrrolopyridines, Pyrrolopyrimidines and Pyrroloazepines-154 |
WO2007106503A2 (en) * | 2006-03-13 | 2007-09-20 | Osi Pharmaceuticals, Inc. | Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors |
JP2009530409A (ja) * | 2006-03-23 | 2009-08-27 | シンタ ファーマシューティカルズ コーポレーション | 炎症及び免疫関連使用用のベンゾイミダゾリル−ピリジン化合物 |
CA2667010A1 (en) * | 2006-10-20 | 2008-05-02 | Irm Llc | Compositions and methods for modulating c-kit and pdgfr receptors |
WO2008075196A1 (en) * | 2006-12-15 | 2008-06-26 | Pfizer Products Inc. | Benzimidazole derivatives |
TWI498115B (zh) | 2007-12-27 | 2015-09-01 | Daiichi Sankyo Co Ltd | 咪唑羰基化合物 |
-
2008
- 2008-12-25 TW TW097150632A patent/TWI498115B/zh active
- 2008-12-26 US US12/811,004 patent/US8536197B2/en active Active
- 2008-12-26 CN CN2008801277565A patent/CN101959882B/zh active Active
- 2008-12-26 JP JP2009548077A patent/JP5586234B2/ja active Active
- 2008-12-26 CA CA2710959A patent/CA2710959C/en active Active
- 2008-12-26 ES ES08867971.7T patent/ES2535085T3/es active Active
- 2008-12-26 EP EP08867971.7A patent/EP2226322B1/en active Active
- 2008-12-26 KR KR1020107013997A patent/KR101578954B1/ko active IP Right Grant
- 2008-12-26 BR BRPI0821855A patent/BRPI0821855B8/pt not_active IP Right Cessation
- 2008-12-26 WO PCT/JP2008/073686 patent/WO2009084614A1/ja active Application Filing
-
2011
- 2011-02-16 HK HK11101476.8A patent/HK1147259A1/xx unknown
-
2013
- 2013-09-13 US US14/027,077 patent/US8927588B2/en active Active
-
2014
- 2014-07-22 JP JP2014149113A patent/JP5798221B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
EP2226322A1 (en) | 2010-09-08 |
EP2226322A4 (en) | 2011-06-08 |
CN101959882A (zh) | 2011-01-26 |
BRPI0821855A2 (pt) | 2015-06-16 |
CN101959882B (zh) | 2013-09-11 |
KR101578954B1 (ko) | 2015-12-18 |
CA2710959C (en) | 2013-10-01 |
HK1147259A1 (en) | 2011-08-05 |
JP2014196369A (ja) | 2014-10-16 |
US8927588B2 (en) | 2015-01-06 |
TW200932221A (en) | 2009-08-01 |
JP5798221B2 (ja) | 2015-10-21 |
US8536197B2 (en) | 2013-09-17 |
CA2710959A1 (en) | 2009-07-09 |
JP5586234B2 (ja) | 2014-09-10 |
ES2535085T3 (es) | 2015-05-05 |
KR20100098657A (ko) | 2010-09-08 |
TWI498115B (zh) | 2015-09-01 |
BRPI0821855B1 (pt) | 2019-08-27 |
JPWO2009084614A1 (ja) | 2011-05-19 |
US20100311966A1 (en) | 2010-12-09 |
WO2009084614A1 (ja) | 2009-07-09 |
US20140073622A1 (en) | 2014-03-13 |
EP2226322B1 (en) | 2015-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0821855B8 (pt) | composto, composição farmacêutica, e, uso de um composto ou sal farmaceuticamente aceitável do mesmo | |
BRPI0714803B8 (pt) | compostos peptidomiméticos de smac, seus usos, e composição farmacêutica | |
BR112015029512A8 (pt) | derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas | |
BR112013004368A2 (pt) | compostos tendo a fórmula geral (i) e composição farmacêutica | |
BRPI0607308A2 (pt) | compostos, composições farmacêuticas e usos dos referidos compostos | |
BRPI0610850A2 (pt) | derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados | |
BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
BRPI0815708B8 (pt) | composto, éster de pró-droga, composição farmacêutica, e, método para tratar uma doença ou condição | |
BRPI0806863B8 (pt) | uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv | |
BR112012021364A2 (pt) | "compostos cicloalquila contendo tienopirimidinas e composições farmacêuticas". | |
BR112013026257A2 (pt) | derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes | |
BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
AR061289A1 (es) | Composiciones farmaceuticas estabilizadas que comprenden fesoterodina | |
BR112013025275A2 (pt) | derivados de cefalosporina e suas composições farmacêuticas | |
BRPI0706992C1 (pt) | composto de fórmula (i) e formulação farmacêutica | |
BR112012013252A2 (pt) | composição farmacêutica tópica, preservativo, composto, e, uso do mesmo | |
BRPI0922804B8 (pt) | composição farmacêutica em uma forma de dosagem sólida compreendendo bendamustina e um excipiente farmaceuticamente aceitável | |
BRPI0906444A8 (pt) | compostos de 4-piridinona e seu uso para câncer | |
BR112012006010A2 (pt) | composto de glicina | |
BRPI0921097B8 (pt) | composto ou seu sal farmaceuticamente aceitável, intermediário do composto, composição farmacêutica e uso do composto | |
BR112018010107A2 (pt) | composição farmacêutica para o tratamento ou prevenção de nash | |
BR112013026361A2 (pt) | derivados de glicosídeo e usos dos mesmos | |
UY30847A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
BR112015014292A2 (pt) | compostos tricíclicos para inibição do canal de cftr | |
PE20151607A1 (es) | Formulaciones de compuestos organicos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/08/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/08/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/08/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) REFERENTE A RPI 2535 DE 06/08/2019,QUANTO AO ITEM (71) NOME DO DEPOSITANTE. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/12/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 15A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2755 DE 24-10-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |